BIO-KEY INTERNATIONAL, INC. (OTCMKTS:BKYID) Files An 8-K Unregistered Sales of Equity Securities

BIO-KEY INTERNATIONAL, INC. (OTCMKTS:BKYID) Files An 8-K Unregistered Sales of Equity Securities
Item 3.02 regarding the unregistered sale of equity securities is incorporated herein by reference.

Story continues below

Item 3.02 Unregistered Sales of Equity Securities.

On April 3, 2018, BIO-key International, Inc. (the “Company”, “we” or “us”) received a conversion notice from Wong Kwok Fong to convert 39,088 shares of the Company’s Series A-1 Convertible Preferred Stock (the “Series A-1 Preferred”). Each share of Series A-1 Preferred has an original issue price of $100.00 and is convertible into shares of Company common stock (“Common Stock”) at a conversion price of $3.60 per share. The forgoing conversion resulted in the issuance of 1,085,778 shares of Common Stock.

On April 3, 2018, we entered into a securities purchase agreement (the “Purchase Agreement”) with Wong Kwok Fong to purchase 91,820 shares of Common Stock in consideration of the conversion of an accrued dividend payable on the Series A-1 Preferred in the amount of $330,552 resulting in a per share purchase price of $3.60. The terms of the Purchase Agreement provided for us to waive the standstill provision (the “Standstill Provision”) included in the securities purchase agreements dated October 29, 2015 and November 11, 2015 by and between the Company and Wong Kwok in order to permit him to purchase the forgoing shares. The Standstill Provision remains in full force and effect and prevents Wong Kwok Fong, either alone or together with any other person, from acquiring additional shares of the Common Stock or any of the Company’s assets, soliciting proxies, or seeking further representation on the Company’s board of directors. Wong Kwok Fong, is the Company’s Managing Director of Hong Kong Operations, a director of the Company, and a principal stockholder of the Company and, therefore, has an interest in the transactions described herein.

The foregoing shares were issued in a private placement transaction to an exemption from registration provided by Section 4(a)(2) of the Securities Act of 1933, as amended, without general solicitation or advertising of any kind and without payment of placement agent or brokerage fees to any person.

Item 9.01

Financial Statements and Exhibits


BIO KEY INTERNATIONAL INC Exhibit
EX-10.1 2 ex_109803.htm EXHIBIT 10.1 ex_109803.htm Exhibit 10.1   CONFIDENTIAL   SECURITIES PURCHASE AGREEMENT   THIS SECURITIES PURCHASE AGREEMENT (this “Agreement”) is entered into and effective simultaneously with the execution of this Agreement on this 3rd day of April 2018,…
To view the full exhibit click here

About BIO-KEY INTERNATIONAL, INC. (OTCMKTS:BKYID)

BIO-key International, Inc. develops and markets fingerprint biometric identification and identity verification technologies, cryptographic authentication-transaction security technologies, as well as related identity management and credentialing software solutions. The Company is also engaged in developing automated, finger identification technology that supplements or compliments other methods of identification and verification, such as personal inspection identification, passwords, tokens, smart cards, identity cards, public key infrastructure (PKI), credit card, passports, driver’s licenses, one-time password (OTP) or other form of possession or knowledge-based credentialing. Its solutions identify individuals and verify, or confirm, their identity before granting access to, among other things, corporate resources, subscribed data and services, Web portals, applications, physical locations or assets.

An ad to help with our costs